| scholarly article | Q13442814 |
| P50 | author | Charles Rudin | Q42609280 |
| Marjorie Zauderer | Q42876441 | ||
| Clemens O. Hanemann | Q46766795 | ||
| Matthias A. Karajannis | Q47163156 | ||
| John T Poirier | Q56953389 | ||
| P2093 | author name string | Jonathan Cooper | |
| Lu Zhou | |||
| Elisa de Stanchina | |||
| Virginia Ojeda | |||
| Filippo G Giancotti | |||
| Qingwen Xu | |||
| Milica Pavlovic | |||
| Kamalika Moulick | |||
| P2860 | cites work | A tight junction-associated Merlin-angiomotin complex mediates Merlin's regulation of mitogenic signaling and tumor suppressive functions | Q24299493 |
| Cockayne syndrome A and B proteins differentially regulate recruitment of chromatin remodeling and repair factors to stalled RNA polymerase II in vivo | Q24300037 | ||
| Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus | Q24300692 | ||
| Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus | Q24300770 | ||
| Structural insights into NEDD8 activation of cullin-RING ligases: conformational control of conjugation | Q24314520 | ||
| Genome sequencing identifies a basis for everolimus sensitivity | Q24631915 | ||
| The molecular basis of CRL4DDB2/CSA ubiquitin ligase architecture, targeting, and activation | Q27675805 | ||
| Function and regulation of cullin-RING ubiquitin ligases | Q28131707 | ||
| Ubiquitin E3 ligase CRL4(CDT2/DCAF2) as a potential chemotherapeutic target for ovarian surface epithelial cancer | Q28674964 | ||
| mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt | Q29547767 | ||
| An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer | Q29616732 | ||
| Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis | Q30357776 | ||
| Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors. | Q30388655 | ||
| mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma | Q30415483 | ||
| Therapeutic potential of HSP90 inhibition for neurofibromatosis type 2. | Q30418605 | ||
| NEDD8-targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells | Q30429284 | ||
| Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling | Q30437229 | ||
| Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1. | Q33819404 | ||
| The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma | Q34190027 | ||
| Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship | Q34193347 | ||
| Dynamics of cullin-RING ubiquitin ligase network revealed by systematic quantitative proteomics | Q34433677 | ||
| Neddylation promotes ubiquitylation and release of Ku from DNA-damage sites. | Q34474077 | ||
| Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors | Q34496360 | ||
| Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling | Q35370616 | ||
| Identification of IRS-1 Ser-1101 as a target of S6K1 in nutrient- and obesity-induced insulin resistance | Q35945000 | ||
| Tumor suppressor protein Lgl mediates G1 cell cycle arrest at high cell density by forming an Lgl-VprBP-DDB1 complex | Q36063647 | ||
| New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment | Q36205186 | ||
| Multimodal activation of the ubiquitin ligase SCF by Nedd8 conjugation | Q37101488 | ||
| NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth | Q37275182 | ||
| Molecular insights into NF2/Merlin tumor suppressor function | Q38204110 | ||
| Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations | Q38790079 | ||
| GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway | Q39458307 | ||
| Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade. | Q40361501 | ||
| PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest | Q40702262 | ||
| A new patient-derived orthotopic malignant meningioma model treated with oncolytic herpes simplex virus. | Q40867510 | ||
| A negative feedback signaling network underlies oncogene-induced senescence | Q43116108 | ||
| Treatment of schwannomas with an oncolytic recombinant herpes simplex virus in murine models of neurofibromatosis type 2. | Q45420889 | ||
| Merlin regulates transmembrane receptor accumulation and signaling at the plasma membrane in primary mouse Schwann cells and in human schwannomas. | Q54785852 | ||
| Upregulation of the Rac1/JNK signaling pathway in primary human schwannoma cells | Q73424194 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 8 | |
| P304 | page(s) | 1693-1704 | |
| P577 | publication date | 2017-05-03 | |
| P1433 | published in | Molecular Cancer Therapeutics | Q2363144 |
| P1476 | title | Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses NF2 Loss-Driven Tumorigenesis | |
| P478 | volume | 16 |
| Q47138523 | Essential signaling in NF2 loss-related tumours: the therapeutic potential of CRL4DCAF1 and mTOR combined inhibition |
| Q64039710 | From process to progress-2017 International Conference on Neurofibromatosis 1, Neurofibromatosis 2 and Schwannomatosis |
| Q49996923 | Heterogeneous Contributing Factors in MPM Disease Development and Progression: Biological Advances and Clinical Implications |
| Q55355075 | NF2/Merlin Inactivation and Potential Therapeutic Targets in Mesothelioma. |
| Q52663125 | Progress in the Management of Malignant Pleural Mesothelioma in 2017. |
| Q48538797 | Protein neddylation and its alterations in human cancers for targeted therapy |
| Q52642770 | Targeting the Hippo Pathway Is a New Potential Therapeutic Modality for Malignant Mesothelioma. |
Search more.